Top Markets
Coin of the day
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
Peringkat dalam Saham #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Harga Saham
$0.00042815
Terakhir disinkronkan: 2024-02-27
Kapitalisasi Pasar
$13.55K
Perubahan (1 hari)
0.03%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan ReNeuron Group plc (RENE)

Kategori

Rasio P/S untuk ReNeuron Group plc (RENE)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari ReNeuron Group plc, rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk ReNeuron Group plc dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR